Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS

计划入组 273 人 · 首次发布于 2024 年 8 月 12 日

Polymorphisms in ENAM, AMBN, and KLK4 Contribute to DCS.

计划入组 204 人 · 首次发布于 2024 年 4 月 3 日

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

计划入组 37 人 · 首次发布于 2022 年 7 月 11 日

Anti-KLK5/KLK7 bispecific antibody(Genentech)

TKM-PLK1

KLK3 inhibitors(Merck)

DiaMedica Receives SAHPRA Approval to Commence Phase II Preeclampsia Trial with DM199

DiaMedica Therapeutics Appoints Julie Krop as Chief Medical Officer to Advance DM199 Development

DiaMedica Therapeutics Secures $30.1 Million to Advance DM199 for Preeclampsia and Fetal Growth Restriction